Primary Specialty: Oncologist
Experience: 35+ Years
Training Medical Education:
Guido Marcucci MD is a practicing medical oncologist with focus on leukemia, hematologic malignancies and hematopoietic stem cell transplantation. He received his MD degree from the Catholic University in Rome, Italy and completed his US training in Internal Medicine through the State University of New York and in Medical Oncology at Roswell Park Cancer Institute, both in Buffalo, NY.
He is currently Professor in the Department of Hematology, Professor and the founding Chair of the Department of Hematologic Malignancies Translational Science, the founding Chief of the Division of Leukemia and the founding Director of the Gehr Family Center for Leukemia Research at City of Hope Comprehensive Cancer Center (CCC), Duarte, California. He also directs the COH Hematopoietic Tissue Biorepository. He moved to COH in 2014 from the Ohio State University (OSU), where he was Professor in the Division of Hematology, Associated Director for Translational Research for the OSU CCC and the Charles A Doan Chair of Medicine. He also has participated in the Oncology Cooperative Group Alliance, previously serving as the Chair of the Leukemia Translational Science Committee, and more recently as one of the Vice-Chairs of the Leukemia Committee. He has been recently elected Member of the Association of American Physicians.
In his more than 25 years of academic work, Dr Marcucci has authored more than 400 peer-reviewed papers published in high-impact factor journals including New England Journal of Medicine, Nature Medicine, Cancer Cells, Journal of Clinical Oncology, Blood, Cancer Research among others. Dr Marcucci has chaired several single and multi-institutional clinical trials in leukemia. Dr Marcucci’s laboratory work is focused on understanding the basic mechanisms of homeostasis and survival of leukemic stem cells, the discovery of new cancer drugs and the development of mathematical models for early prediction of leukemia development and response to treatment. He has been uninterruptedly funded by the NCI since 2001 through different grant mechanisms including P50, R01, R21, U01 and K08.